MEDICAL DEVICES

GeneQuantum Healthcare's Two Next Generation Bioconjugate Drugs, GQ1005 and GQ1007, Have Been Approved for Clinical Trials in Australia

GeneQuantum Healthcare | May 16, 2022

GeneQuantum Healthcare's

GeneQuantum Healthcare Co., Ltd. a global innovative biotechnology company dedicated to the development of bioconjugate drugs, announced that two of the company's bioconjugate drug candidates have won the approval for clinical trials in Australia, further enhancing GeneQuantum's pipelines in the clinical stage. They are GQ1005, an ADC with an excellent bystander killing effect, and GQ1007, a first-in-class antibody-immune-agonist-conjugate both with global intellectual property rights.

"The core technologies that we have focused on since the founding of GeneQuantum, bring the company into the harvest period for exciting next generation bioconjugate drugs. The EC approval of GQ1005 and GQ1007 in Australia is an important milestone for the company. More than once, GeneQuantum's enzymatic site-specific conjugation platform and the stable linker technology have demonstrated the advantages through several IND enabled drug candidates.  GeneQuantum conjugation technologies are widely compatible to different molecular modalities with various Mechanism of Action. Committed to the core value of "breakthrough for humanity", GeneQuantum is dedicated to developing safe, effective, and affordable novel therapeutics for patients with cancer around the world."

 

Dr. Gang Qin, founder, Chairman and Chief Executive Officer

 

About GeneQuantum Healthcare Co., Ltd.

GeneQuantum Healthcare Co., Ltd. is a global biotechnology company dedicated to the development of innovative biotherapeutics. The company is focused on the development of next generation bioconjugate therapeutics to address the unmet medical needs of patients globally.  

This press release contains statements relating to GeneQuantum's future business, future events or developments, and related statements may constitute forward-looking statements. Statements are based on current expectations and assumptions that are subject to risks and uncertainties, which may cause actual results to differ materially. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, follow-up clinical data and analysis; factors that may cause any delay, transfer or change; regulatory authority decision whether and when to approve drug applications; factors that may lead actual results to seriously deviate from current expectations, etc. No forward-looking statement can be guaranteed. Except as required by applicable laws, GeneQuantum assumes no obligation to update or revise any forward-looking information or statements.

Spotlight

Rafael Grossman, surgeon, teacher, and healthcare futurist, shares the many ways 5G can benefit the healthcare system. 5G could help improve all aspects of healthcare from prevention, treatments, rehabilitation, and teaching with high speeds and low latency. More on New T-Mobile & 5G.

Spotlight

Rafael Grossman, surgeon, teacher, and healthcare futurist, shares the many ways 5G can benefit the healthcare system. 5G could help improve all aspects of healthcare from prevention, treatments, rehabilitation, and teaching with high speeds and low latency. More on New T-Mobile & 5G.

Related News

HEALTH TECHNOLOGY

Conformis Announces New Agreement with Vizient for Personalized Orthopedic Implants

Conformis, Inc. | August 02, 2022

Conformis, Inc. a leading medical device company that features personalized knee and hip replacement products, announced it has entered into a multi-year agreement with Vizient, Inc., the nation's largest member-driven health care performance improvement company. “We are excited to offer personalized orthopedic implants to Vizient’s large membership of healthcare facilities through this contract. As more orthopedic patients and surgeons seek personalized solutions, increased awareness and ease of access to our product portfolio is more important than ever. The Vizient agreement connects us to a significant number of providers, many of which have limited access and awareness of our products and our new Platinum Services Program,” Mark Augusti, Chief Executive Officer and President of Conformis The agreement gives increased access to the entire Conformis knee and hip portfolio to Vizient’s membership base, which is comprised of academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks and non-acute health care providers, and includes Identity Imprint™, a personalized knee replacement system; Image-to-Implant® Platinum Services Program, a patient-elected deluxe upgrade option to obtain a fully personalized knee replacement implant; and, Cordera™ Match Hip System, a personalized primary hip replacement solution. Conformis implants improve efficiency and reduce overall costs for medical facilities. Researchers at the University of Washington in Seattle found that fully personalized total knee arthroplasty is cost-effective in comparison to a standard, off-the-shelf implant. Ongoing research suggests that fully personalized implants further reduce total costs to the healthcare system because patients recover more quickly and are less likely to require follow-up corrective surgeries. About Conformis, Inc. Founded in 2004, Conformis is a medical technology company focused on advancing orthopedic patient care and creating a world without joint pain. Its product portfolio is designed to maximize surgeon and patient choice by offering fully personalized solutions through its Image-to-Implant® Platinum Services℠ Program as well as data-informed, standardized solutions that combine many benefits of personalization with the convenience and flexibility of an off-the-shelf system. Conformis’ sterile, just-in-time, Surgery-in-a-Box™ delivery system is available with all of its implants and personalized, single-use instruments. Conformis owns or exclusively in-licenses issued patents and pending patent applications that cover personalized implants and patient-specific instrumentation for all major joints.

Read More

HEALTH TECHNOLOGY

Henry Schein Acquires Midway Dental Supply

Henry Schein, Inc. | August 30, 2022

Henry Schein, Inc. the world’s largest provider of health care solutions to office-based dental and medical practitioners, announced the acquisition of Midway Dental Supply, a full-service dental distributor serving dental offices and dental laboratories across the Midwestern United States. Henry Schein acquired 100% of Midway Dental, which was founded in 1987 by the late Roger Abigt, and is headquartered in Livonia, Michigan. This transaction is expected to be modestly dilutive to Henry Schein’s earnings per share in fiscal year 2022 and increasingly accretive thereafter. Financial terms were not disclosed. Midway Dental’s sales from 2021 were approximately $110 million, including nearly $20 million in sales of personal protective equipment (PPE) and COVID-19 related products. Midway Dental offers a comprehensive portfolio of dental consumable merchandise, equipment, services, and education products to nearly 7,000 customers, which will be immediately consolidated into Henry Schein’s U.S. Dental business. The integration of Midway Dental’s sales and service team with Henry Schein’s network of trusted advisors will further advance the Company’s efforts to deliver customized solutions and technology-driven products and services to help our dental customers meet the needs of patients. “Over the past 35 years, Midway Dental has earned an excellent reputation within the industry, grounded by a strong commitment to customer service and industry leadership that is aligned with Henry Schein’s values-based culture and high-touch, full-service business model,” said Stanley M. Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein. “Midway Dental’s vision to establish a nationwide footprint aligns with Henry Schein’s commitment to provide the products and services customers can rely on to work more efficiently and deliver high-quality patient care more effectively.” Led by CEO Steven Kizy, Midway Dental has approximately 200 employees, including 55 sales representatives and 50 service technicians. Mr. Kizy will join Henry Schein as Vice President, Strategic Development-U.S. Dental. “As part of Henry Schein, Midway Dental will have access to new capabilities, including an expanded portfolio of solutions to serve our customers even better while offering our staff exciting new career possibilities. More specifically, Midway Dental’s customers will benefit from the vast array of Henry Schein branded products as well as the latest digital technologies that are modernizing dental practices. We are delighted to be joining forces with the world’s leading provider of dental products and services.” Mr. Kizy About Henry Schein, Inc. Henry Schein, Inc. is a solutions company for health care professionals powered by a network of people and technology. With more than 22,000 Team Schein Members worldwide, the Company's network of trusted advisors provides more than 1 million customers globally with more than 300 valued solutions that help improve operational success and clinical outcomes. Our Business, Clinical, Technology, and Supply Chain solutions help office-based dental and medical practitioners work more efficiently so they can provide quality care more effectively. These solutions also support dental laboratories, government and institutional health care clinics, as well as other alternate care sites. Henry Schein operates through a centralized and automated distribution network, with a selection of more than 120,000 branded products and Henry Schein private-brand products in stock, as well as more than 180,000 additional products available as special-order items. A FORTUNE 500 Company and a member of the S&P 500® index, Henry Schein is headquartered in Melville, N.Y., and has operations or affiliates in 32 countries and territories. The Company's sales reached $12.4 billion in 2021, and have grown at a compound annual rate of approximately 12.5 percent since Henry Schein became a public company in 1995.

Read More

HEALTH TECHNOLOGY

Sense and TECOmedical Sign Distribution Agreement for Germany, Austria, Switzerland

Sense Biodetection | September 02, 2022

Global molecular diagnostics innovator, Sense Biodetection announced it has entered into a strategic agreement with TECOmedical for the non-exclusive distribution of Sense’s Veros COVID-19, the first test on the rapid, instrument-free, point-of-care Veros molecular testing platform. The self-contained, single-use Veros COVID-19 product produces PCR-quality results in about 15 minutes, unconstrained by a reader or need for external power. TECOmedical, a Eurobio Scientific Company, is a leading specialty medical distributor with proven success developing new markets with innovative technology. Effective immediately in Germany and Austria, and pending regulatory approval in Switzerland, the agreement is the latest in Sense’s planned EU distribution partnerships as it commercializes its Veros platform. “We are delighted to partner with TECOmedical to bring Veros COVID-19 to the market, building on the impressive reputation that TECOmedical has established with their customers,” stated Ryan Roberts, Chief Commercial Officer of Sense. “We’re optimistic that by adding the instrument-free Veros COVID-19 to their diagnostic portfolio, TECOmedical’s customers will be able to take advantage of a laboratory-quality molecular test that can enable improved access and faster diagnosis, helping them to provide exceptional care for their patients right at the point of use.” “We are always looking for innovative technologies that address an unmet need. Being able to offer an instrument free, PCR-quality result in minutes right at the Point of Care reflects our commitment to customers to bring solutions that help them overcome limitations of existing technologies and improve care. We are excited to launch Veros COVID-19 now and are eagerly anticipating an expanded Veros test menu in the future.” Marieluise Wippermann, CEO of TECOmedical Veros is the first and only instrument-free, single-use, rapid, point-of-care molecular diagnostic testing platform that produces lab-quality results in about 15 minutes. Using a proprietary, rapid molecular amplification technology, Veros aims to help to improve access to rapid, highly accurate, point of care testing for many more people, and help reduce the spread of COVID-19 with faster, more precise diagnoses. Veros COVID-19’s clinical performance was established in one of the most comprehensive clinical trials in COVID-19 diagnostic testing conducted to date. The multicentre study prospectively enrolled nearly 300 evaluable subjects during both the Delta and Omicron variant surges of the pandemic. All study sites represented near-patient testing / point-of-care environments, with all test operators reporting no prior formal laboratory training or experience. 100% of operators agreed the Veros COVID-19 was easy-to-use, read and understand the results, with minimal hands-on time required from start to finish. As the virus continues to evolve, Veros COVID-19 has maintained 100% conservation in all Variants of Interest and Concern identified to date by WHO and the US CDC, including all Omicron sub-variants. About Sense Biodetection Sense Biodetection is a global molecular diagnostics company focused on empowering patients and transforming healthcare access and affordability by bringing lab-quality results through easy-to-use, rapid, disposable molecular tests without the constraints of an instrument. The company's Veros product platform will enable widespread testing to enhance patient access, improve patient health and lower systemic healthcare costs. Backed by respected investors, such as Koch Disruptive Technologies, Cambridge Innovation Capital, Earlybird Health and Mercia Asset Management, Sense has launched its first product, Veros COVID-19, and is growing rapidly while building a portfolio of tests for other diseases. About TECOmedical The Swiss-based TECOmedical Group, a Eurobio Scientific company, with subsidiaries in Germany and Austria is a leading provider of in-vitro specialty test systems in medical diagnostic, based on Immunosorbent, Immunofluorescence and Molecular methodologies.

Read More